Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CNTO provided a clinical progress update in its quarterly conference call.
The 1,400-patient European Capture trial of CentoRx gpIIb/IIIa inhibitor for unstable angina, renamed ReoPro, is
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury